StockNews.com Begins Coverage on Repligen (NASDAQ:RGEN)

StockNews.com assumed coverage on shares of Repligen (NASDAQ:RGEN – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. RGEN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft cut their price objective on Repligen from $180.00 to $165.00 in a […]

Related Keywords

United States ,America ,Craig Hallum ,Martind Madaus ,Stifel Nicolaus ,Repligen Corp ,Repligen Company Profile ,Keycorp ,Vanguard Group Inc ,Pricet Rowe Associates Inc ,Deutsche Bank Aktiengesellschaft ,Invesco Ltd ,Sands Capital Management ,Get Rating ,Bank Aktiengesellschaft ,Moderate Buy ,Director Martin ,Capital Management ,State Street Corp ,Street Corp ,Asia Pacific Region ,Repligen Daily ,Repligen ,Nasdaq Rgen ,Rgen ,Medical ,75991610 ,Initiated Coverage ,Stocknews Com ,